SINATIC 10 mg
Kullanım Talimatı
Each tablet contains: 5 mg and 10 mg of Ramipril.
Ramipril inhibits angiotensin converting enzyme (ACE) in human subjects and animals. (ACE) is a peptidyl dipeptidase that catalyzes the conversion of angiotensin (I) to the vasoconstrictor substance, angiotensin (II). Angiotensin (II) also stimulates aldosterone secretion by the adrenal cortex.
Inhibition of (ACE) results in decreased plasma angiotensin (II), which leads to decreased vasopressor activity and to decreased aldosterone secretion.
The letter decrease may result in a small increase of serum Potassium.
Inhibition of (ACE) results in decreased plasma angiotensin (II), which leads to decreased vasopressor activity and to decreased aldosterone secretion.
The letter decrease may result in a small increase of serum Potassium.
Ramipril acts as a prodrug of the diacid Ramipril, its active metabolite. Following oral administration at least 50 to 60% is absorbed. Ramipril is metabolized in the liver to Ramipril when other metabolites are inactive. Peak plasma concentration of Ramipril are achieved 2 to 4 hours after an oral dose of Ramipril.
Ramipril is about 56% bound to plasma proteins. About 60% of an oral dose of Ramipril is excreted in the urine, the rest in the feces. The effective half-life for accumulation of Ramipril is 13 to 17 hours following multiple doses of Ramipril 5 to 10mg. but is much longer for doses of 1.25 to 2.Smg daily.
The clearance of Ramipril is reduced in renal impairment.
Ramipril is about 56% bound to plasma proteins. About 60% of an oral dose of Ramipril is excreted in the urine, the rest in the feces. The effective half-life for accumulation of Ramipril is 13 to 17 hours following multiple doses of Ramipril 5 to 10mg. but is much longer for doses of 1.25 to 2.Smg daily.
The clearance of Ramipril is reduced in renal impairment.
Ramipril as one of (ACE) inhibitors have a similar side effects such as, hypo-tension, dizziness, fatigue, headache, gastrointestinal disturbances, taste disturbances, persistent dry cough and other upper respiratory tract symptoms, skin rashes, angio-edema, hyper-sensitivity reactions, renal impairment, hyperemia, hypo-natraemia and blood disorders.
Other side effect reported with Ramipril include chest pain, palpitation, tachycardia, stomatitis, abdominal pain, pancreatitis, hepotocellular injury or cholestatic jaudice, alopecia, muscle cramps and impotence.
Most of the side effects of (ACE) inhibitors are reversible on wit arawing therapy.
Other side effect reported with Ramipril include chest pain, palpitation, tachycardia, stomatitis, abdominal pain, pancreatitis, hepotocellular injury or cholestatic jaudice, alopecia, muscle cramps and impotence.
Most of the side effects of (ACE) inhibitors are reversible on wit arawing therapy.
- Ramipril should not be used in patients with
aortic stenosis or outflow tract obstruction.
- Ramipril should be used with cautions in patients with renal vascular disease.
- Renal function should be assessed in all patients prior to administration of Ramipril and should be monitored during therapy.
- Ramipril should be used with cautions in patients with heart failure and patients who are likely to be salt or water depleted.
- Treatment in these patients should be started under close medical supervision.
- Ramipril should be used with cautions in patients with a history of wrecked vascular unknown heredity. - Indications:
- SINATIC: It is used in the treatment of hypertension,
heart failure and following myocardial infarction to improve survival in patients with clinical evidence of heart failure.
It is also used to reduce the risk of cardiovascular events in patients with certain risk factors.
aortic stenosis or outflow tract obstruction.
- Ramipril should be used with cautions in patients with renal vascular disease.
- Renal function should be assessed in all patients prior to administration of Ramipril and should be monitored during therapy.
- Ramipril should be used with cautions in patients with heart failure and patients who are likely to be salt or water depleted.
- Treatment in these patients should be started under close medical supervision.
- Ramipril should be used with cautions in patients with a history of wrecked vascular unknown heredity. - Indications:
- SINATIC: It is used in the treatment of hypertension,
heart failure and following myocardial infarction to improve survival in patients with clinical evidence of heart failure.
It is also used to reduce the risk of cardiovascular events in patients with certain risk factors.
SINATIC is contraindicated in patients who are hypersensitive to this product or any other angiotensin converting enzyme inhibitor.
SINATIC should not be used in pregnant women and during breast feeding (Lactation ).
- Excessive hypotension may occur when (ACE) inhibitors are used concurrently with diuretics, other antihypertensive or other agents including alcohol that lower blood pressure.
- Potassium supplements should be stopped before initiating (ACE) inhibitor in patients with heart failure.
- The adverse effects of (ACE) inhibitors on the kidneys may be potentiated by other drugs such as NSAIDs that can affect renal function.
- Potassium supplements should be stopped before initiating (ACE) inhibitor in patients with heart failure.
- The adverse effects of (ACE) inhibitors on the kidneys may be potentiated by other drugs such as NSAIDs that can affect renal function.
- The initial dose of 1.25 once daily is given by mouth, the first dose should be given at bed time, for patients who are taking diuretics they should "if possible" stop taking these drugs for at least 2-3 days before treating with SINATIC, then they can continue afterward if it is necessary.
- Following myocardial infarction, treatment with SINATIC tablets "ramipril" may be started in hospital 3 to 10 days after the infarction at a usual initial dose of2.5 mg twice daily, increased after two days to 5 mg twice daily.
- The usual maintenance: dose is 2.5 to 5 mg daily as a single dose, although up to 10 mg daily may be required.
- In the management of heart failure, the initial dose of 1.25 mg once daily, the usual maximum dose is 10 mg daily.
- The usual maintenance dose in 2.5 to 5 mg twice daily.
- For the prophylaxis of cardiovascular events in patients considered to be at high risk, SINATIC tablets "ramipril" is given in.-an initial dose of 2.5 mg once daily. The dose should be increased, if tolerated, to 5 mg once daily after I week. Then to the usual maintenance dose of 10 mg once daily after a further 3 weeks. - In patients with hypertension or recent myocardial infarction it may also be given in divided doses.
- Following myocardial infarction, treatment with SINATIC tablets "ramipril" may be started in hospital 3 to 10 days after the infarction at a usual initial dose of2.5 mg twice daily, increased after two days to 5 mg twice daily.
- The usual maintenance: dose is 2.5 to 5 mg daily as a single dose, although up to 10 mg daily may be required.
- In the management of heart failure, the initial dose of 1.25 mg once daily, the usual maximum dose is 10 mg daily.
- The usual maintenance dose in 2.5 to 5 mg twice daily.
- For the prophylaxis of cardiovascular events in patients considered to be at high risk, SINATIC tablets "ramipril" is given in.-an initial dose of 2.5 mg once daily. The dose should be increased, if tolerated, to 5 mg once daily after I week. Then to the usual maintenance dose of 10 mg once daily after a further 3 weeks. - In patients with hypertension or recent myocardial infarction it may also be given in divided doses.
Store in a dry place below 30c
- 20 tablets in 2 blisters for 5 mg.
- 20 tablets in 2 blisters for 10 mg.
- 20 tablets in 2 blisters for 10 mg.